9 Things Cannabis Investors Should Know
The swift regulatory changes taking place in the global cannabis sector are almost without modern precedent.
While some find the situation analogous to the repeal of Prohibition in the United States, it’s also fair to point out that such events happened 85 years ago in the midst of the Great Depression. It was a long time ago, and in a very different economic climate.
Today’s infographic comes to us from Evolve ETFs, and it shows what investors should know as the legal cannabis sector comes out of the dark.
What Cannabis Investors Should Know
Since there is so much happening at once with little precedent for what such a market will look like, it’s worth summing up the sector’s potential in broad strokes:
1. Global Size
According to research from The Brightfield Group, the size of the legal cannabis sector is expected to surge from $7.7 billion to $31.4 billion between 2017 and 2021.
Currently the recreational market makes up only 37% of the global total – but by 2021, that will rise to 57%.
2. Versatile Uses
Cannabis comes in different forms. One gram of dried cannabis is roughly equivalent to:
- 5g of fresh cannabis
- 15g of edible product
- 70g of liquid product
- 0.25g of concentrates
- 1 cannabis plant seed
These can be used in various medical applications, including to fight chronic pain, migraines, anxiety, multiple sclerosis, and nausea. Cannabis can also be used to treat Alzheimer’s, PTSD, and cancer.
3. North American Growth
By 2021, it’s estimated that North American sales will make up 86% of the global market. Specifically, the U.S. legal market is projected to hit $18.1 billion by that time, while the Canadian legal market is expected to be $8.9 billion in that same year.
4. A Shifting Legal Landscape
Canada will be the first G7 country to legalize cannabis at a federal level.
In the United States, recreational cannabis is already legalized in nine states – but this could change swiftly as various states undergo referendums.
5. European Markets
In 2017, the legal market for cannabis is estimated to be just $0.11 billion, but by 2021 it will have expanded to $3.8 billion.
According to The Brightfield Group, growth will be quite impressive in Western Europe: Germany’s market will grow at a 284% annual rate, the Netherlands at 364%, and Spain at 334%.
6. Rest of the World
Although markets outside of North America and Europe will not see the same growth in absolute dollar terms, the legal cannabis market will still expand from $80 million to $350 million, led by activity in Latin America.
7. Pharmaceutical Research
Israel has a special place in the cannabis world – the country is world leader in medical cannabis research, and industry expects that it will eventually translate into a $1 billion export opportunity. That said, export plans have hit a recent road bump.
8. Investment Activity
Compare the start of 2018 to that of 2017, and you’ll see an impressive difference in investment activity.
For this we use Canada with its impending recreational legalization as an example: in the first six weeks of 2018, investment was up nearly 7x over the previous year. Further, the average deal size increased from $5.6 million to $18.7 million.
Meanwhile, the Canadian Cannabis Index rose 201% between January 2017 and January 2018.
9. How to Invest?
There are a variety of ways to gain exposure to the sector, including:
- Licensed producer stocks
- Biotech stocks
- Ancillary services stocks
- Licensed retailer stocks
- Cannabis ETFs
Regardless of how you play it, the legal cannabis sector is coming out of the dark – and it will be interesting to see how the industry takes shape.
Consumer Archetypes Shaping the European CBD Industry
This infographic visualizes the non-consumer and consumer archetypes that could be position Europe as the leader in global cannabis consumption.
Consumer Archetypes Shaping the European CBD Industry
View the high-resolution of the infographic by clicking here.
With a colossal base of 500 million potential cannabis consumers, and laws that are loosening at a steady pace, Europe could soon emerge as the global cannabis leader.
Cannabidiol, better known as CBD, has become one of the most popular forms of cannabis in the European market, but little is known about the consumers who are reaching for it.
New Frontier Data identified a spectrum of archetypes in an effort to better understand their consumption patterns.
What Makes Europe Different?
Although Europe’s cannabis market is still in early stages, the proximity of countries could be instrumental in how quickly it grows. Widespread legalisation could be accelerated due to neighbouring countries lowering the barriers for others—also known as The Domino Effect.
A total of 22 countries have now legalised some form of medical cannabis, while other countries have decriminalised recreational cannabis or have pledged to fully legalise it in the coming years.
There is a 60% to 70% chance that cannabis will be legal across Europe within the next three years, but more research is key to unlocking growth in this market—and that includes gaining a full understanding of what consumers want.
CBD Consumer Archetypes
New Frontier Data identified five CBD consumer archetypes and four non-consumer archetypes, based on their attitudes, beliefs, and experiences. The CBD consumer archetypes are as follows:
- The Exuberant & Intense (11%): As advocates of the CBD movement, this group is devoted to trying different products and spends more than any other archetype in the process.
- The Integrative & Consistent (29%): CBD has become an essential component in achieving a healthy lifestyle for this group, resulting in them consuming it at least once a week and putting them in second place for highest overall spend.
- The Sceptical & Limited (20%): CBD products are used in moderate frequency, but have not been incorporated into this group’s lifestyle as they are generally wary of health claims. However, more information may soothe the concerns of this group over time.
- The Receptive & Reserved (23%): Consuming a narrow range of products in moderate frequency, this group are more comfortable trying products based on recommendations from friends and family. Over time, as more people in their inner circle try different products, they will also gain confidence to follow.
- The Ambivalent & Experimental (17%): This group will not consider purchasing CBD products themselves, but will consume products when they are shared by friends and family. While their beliefs are more conservative, new products could tempt them to make CBD part of their routine.
Interestingly, up to 98% of surveyed consumers claim that CBD has positively affected their quality of life in some way. In terms of product preferences, tinctures/oils are a consumer favourite, with a large portion of people using CBD to unwind.
Less than half of all non-consumers have heard of CBD. While some of them are not open to changing behaviors, others could soon convert to a consumer archetype, provided information and legalisation becomes more commonplace.
- Unaware & Uninterested (43%): Having never come across CBD products online or in store, this group is broadly uninterested in learning more, but may be open to experimenting as the market becomes more regulated.
- Knowledgeable & Primed (28%): This group expresses a strong belief in the benefits of CBD and their curiosity to learn more makes them the most likely group to become consumers in the next six months.
- Informed & Indifferent (19%): A wide exposure to CBD products does not translate to intent to purchase, potentially due to this group’s lack of awareness regarding CBD’s beneficial properties.
- Cautious & Curious (10%): Despite a strong curiosity towards CBD products, they remain apprehensive about the safety and legality of them.
Overall, 34% of non-consumers are curious about trying CBD products—which could yield significant growth for the cannabis industry in the coming years.
A New Successor to the Throne
The recent COVID-19 outbreak has also sparked major discussion around the use of cannabis. Some parts of the world have declared it as “essential”, as consumers use products to alleviate pandemic-fuelled anxiety, which has resulted in a huge sales boost for the industry.
This will likely translate to Europe, where almost half of CBD consumers claim its therapeutic benefits are their primary reason for use.
The reality is that the potential for European cannabis growth is significant, and to achieve this, both consumer and non-consumer motivations should be considered.
Visualizing the Huge Potential of Minor Cannabinoids
While the broader cannabis market is estimated to reach $45B by 2024, we’ve only scratched the surface in harnessing the potential of minor cannabinoids.
The Huge Potential of Minor Cannabinoids
Hemp and marijuana are increasingly recognized for their exciting investment potential.
Due to their growing list of health benefits, the dominant conversation tends to center around the most abundant cannabinoids—cannabidiol (CBD) and tetrahydrocannabinol (THC). As a result, the cannabinoid market is estimated to reach almost $45 billion by 2024.
But CBD and THC are just two cannabinoids out of over a hundred that have been discovered to date. Today’s graphic from Trait Biosciences explores the hidden potential of the lesser-known minor cannabinoids, and illustrates how they fare in comparison to their major counterparts.
Cannabinoids are chemical compounds found in both hemp and marijuana that mimic compounds found in the human endocannabinoid system. This system is made up of a network of receptors that are involved in physiological processes like mood and memory.
When cannabis is consumed, cannabinoids interact with these receptors and produce different effects depending on the receptors they bind to. Although over a hundred cannabinoids have been found, they are not all created equally. They are typically divided into two categories:
- Major cannabinoids: More plentiful
- Minor cannabinoids: Less plentiful
Regardless of whether a cannabinoid is categorized as major or minor, every cannabinoid starts out as a form of CBG.
CBG-A: The Mother of All Cannabinoids
Cannabigerolic acid, or as it is more commonly known, CBG-A, is the acid precursor to other cannabinoid acids such as THC-A, and CBD-A. When the acids are exposed to heat, or prolonged UV light, they convert to neutral cannabinoids such as CBD and THC.
While CBG is regarded as a minor cannabinoid, it boasts a wide range of benefits that are urging researchers and scientists to take notice:
- Fights inflammation
- Soothes pain
- Reduces nausea
- Slows the spread of cancer cells
- Helps treat glaucoma
CBG could be hugely beneficial in treating a wide variety of diseases, but it’s just one of many minor cannabinoids that could potentially blow CBD and THC out of the water.
The Potential of Minor Cannabinoids
To date, there has been limited research into the power of minor cannabinoids. However, the results from preliminary research look incredibly promising.
|Cannabinoid||Type||Examples of potential medical application|
|Major, psychoactive||Parkinson’s disease, epilepsy, autoimmune diseases|
|Major, non-psychoactive||Epilepsy, schizophrenia|
|Minor, non-psychoactive||Metabolic disorders, colon cancer
|Minor, non-psychoactive||Arthritis, neurodegenerative diseases, nausea, appetite loss
|Minor, non-psychoactive||Chemotherapy-induced nausea/vomiting (CINV), depression|
|Minor, non-psychoactive||Fungal diseases
|Minor, non-psychoactive||Crohn’s disease, bowel disease, certain cancers
|Minor, non-psychoactive||Seizure prevention, Rett syndrome, Duchenne muscular dystrophy (DMD)|
|Minor, non-psychoactive||Osteoporosis, ALS, Muscular dystrophy|
|Minor, non-psychoactive||Could inhibit growth of cancer cells, osteoarthritis, neurological diseases
|Minor, psychoactive||Diabetes, anxiety, PTSD
|Minor, psychoactive||Bacterial infections, ALS ,appetite stimulant
Note: Any potential medical treatment listed here stems from preclinical/animal testing only, and is simply intended to illustrate the potential application of each cannabinoid rather than a proven benefit.
Scientists also recently discovered two new cannabinoids—THC-P and CBD-P—with research showing that THC-P could potentially be 30 times more potent than THC.
The Future of Minor Cannabinoids
FDA-approved CBD drug Epidiolex has sparked a rising interest in minor cannabinoid trials.
In fact, the National Institutes of Health (NIH) has committed to providing funding to strengthen the evidence for minor cannabinoids and their pain relieving properties.
Cannabinoids could also add great value to cancer treatment-related side effects, however, more research is needed to turn potential into proof. With the availability of more robust evidence, the potential medical applications for minor cannabinoids could be much greater than we can imagine.
Advertising2 months ago
How COVID-19 Has Impacted Media Consumption, by Generation
COVID-192 months ago
The Pandemic Economy: What are Shoppers Buying Online During COVID-19?
COVID-192 months ago
Every Vaccine and Treatment in Development for COVID-19, So Far
COVID-191 month ago
The Front Line: Visualizing the Occupations with the Highest COVID-19 Risk
COVID-192 months ago
Visualizing What COVID-19 Does to Your Body
COVID-191 month ago
How COVID-19 Consumer Spending is Impacting Industries
Central Banks2 months ago
The Anatomy of the $2 Trillion COVID-19 Stimulus Bill
Money2 months ago
Mapped: The Wealthiest Person in Every U.S. State in 2020